These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23402081)

  • 21. Advances in bile acid medicinal chemistry.
    Sharma R; Long A; Gilmer JF
    Curr Med Chem; 2011; 18(26):4029-52. PubMed ID: 21824088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
    Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FXR an emerging therapeutic target for the treatment of atherosclerosis.
    Mencarelli A; Fiorucci S
    J Cell Mol Med; 2010 Jan; 14(1-2):79-92. PubMed ID: 20041971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
    Halilbasic E; Fuchs C; Traussnigg S; Trauner M
    Dig Dis; 2016; 34(5):580-8. PubMed ID: 27332721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases.
    Sonne DP
    Eur J Endocrinol; 2021 May; 184(5):R193-R205. PubMed ID: 33630750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
    Modica S; Moschetta A
    FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
    Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
    Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bile Acids as Hormones: The FXR-FGF15/19 Pathway.
    Kliewer SA; Mangelsdorf DJ
    Dig Dis; 2015; 33(3):327-31. PubMed ID: 26045265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
    Watanabe M; Houten SM; Mataki C; Christoffolete MA; Kim BW; Sato H; Messaddeq N; Harney JW; Ezaki O; Kodama T; Schoonjans K; Bianco AC; Auwerx J
    Nature; 2006 Jan; 439(7075):484-9. PubMed ID: 16400329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress and challenges of selective Farnesoid X Receptor modulation.
    Massafra V; Pellicciari R; Gioiello A; van Mil SWC
    Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farnesoid X receptor: A "homeostat" for hepatic nutrient metabolism.
    Massafra V; van Mil SWC
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):45-59. PubMed ID: 28986309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
    Claudel T; Staels B; Kuipers F
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farnesoid X receptor agonists for primary biliary cirrhosis.
    Lindor KD
    Curr Opin Gastroenterol; 2011 May; 27(3):285-8. PubMed ID: 21297469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis.
    Moris D; Giaginis C; Tsourouflis G; Theocharis S
    Curr Med Chem; 2017 May; 24(11):1147-1157. PubMed ID: 28120707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome.
    Portincasa P; Di Ciaula A; Garruti G; Vacca M; De Angelis M; Wang DQ
    Nutrients; 2020 Nov; 12(12):. PubMed ID: 33266235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
    Radun R; Trauner M
    Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR).
    Berrabah W; Aumercier P; Gheeraert C; Dehondt H; Bouchaert E; Alexandre J; Ploton M; Mazuy C; Caron S; Tailleux A; Eeckhoute J; Lefebvre T; Staels B; Lefebvre P
    Hepatology; 2014 May; 59(5):2022-33. PubMed ID: 24037988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear bile acid signaling through the farnesoid X receptor.
    Mazuy C; Helleboid A; Staels B; Lefebvre P
    Cell Mol Life Sci; 2015 May; 72(9):1631-50. PubMed ID: 25511198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors.
    Spinelli V; Chávez-Talavera O; Tailleux A; Staels B
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):138-44. PubMed ID: 26859552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effect of resveratrol on α‑naphthyl isothiocyanate‑induced cholestasis via regulation of the FXR pathway.
    Ding L; Zhang B; Li J; Yang L; Wang Z
    Mol Med Rep; 2018 Jan; 17(1):1863-1872. PubMed ID: 29138819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.